Jaume M. G.
- Country
- Spain
- Department
- Oncological Pediatric Unit
Research Overview
- Phase 2 Evaluation of Naxitamab and Sargramostim in High-Risk Neuroblastoma with Refractory or Incomplete Response in Bone/Bone Marrow
- Phase II Evaluation of RO7435846 in Combination with Multiple Agents for Biomarker-Positive Advanced or Metastatic Solid Tumors
- Phase 1 Multicenter Open-Label Study of Niraparib Tosilate Monohydrate and Dostarlimab in Pediatric Patients with Recurrent or Refractory Solid Tumors
Data & Insights
Has run more than one trial at 36 of 83 partner sites.
Specializations
Pediatric Oncology
The investigator specializes in treating pediatric solid tumors and demonstrates particular expertise in developing therapeutic approaches for young patients. Their research encompasses both conventional and innovative treatment methods for children and adolescents with cancer.
- Solid tumor management in children
- Pediatric cancer therapeutics
- Advanced treatment protocols
Sarcoma Treatment
Focused on treating aggressive bone and soft tissue cancers, with particular emphasis on Ewing sarcoma and osteosarcoma. The investigator works with both primary cases and refractory disease scenarios.
- Refractory sarcoma therapy
- Combination treatment approaches
- Maintenance therapy protocols
Neuroblastoma Care
Specialized in treating high-risk neuroblastoma, particularly focusing on cases with bone and bone marrow involvement. The investigator employs targeted antibody therapies and immunological approaches.
- Immunotherapy applications
- Refractory disease management
- Novel therapeutic combinations
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.